RSCM
VKTX icon

Rock Springs Capital Management’s Viking Therapeutics VKTX Stock Holding History

Rock Springs Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$995K Sell
25,500
-70,500
-73% -$2.28M 0.05% 99
2026
Q1 		$3.12M Buy
+96,000
New +$3.09M 0.18% 77
2024
Q2 		– Sell
-261,000
Closed -$21.4M – 120
2024
Q1 		$21.4M Buy
+261,000
New +$11.6M 0.54% 56
2018
Q4 		– Sell
-200,000
Closed -$3.48M – 143
2018
Q3 		$3.48M Buy
+200,000
New +$2.38M 0.13% 127

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Rock Springs Capital Management's VKTX Position: Q2 2026 in Review

Rock Springs Capital Management reduced its Viking Therapeutics (VKTX) stake by 73% in Q2 2026, selling an estimated $2.28M and leaving 25,500 shares worth $995K. The position accounts for 0.05% of the portfolio, ranked #99.

Rock Springs Capital Management first reported a position in VKTX in Q3 2018 and has held it in 4 quarters since. The position peaked at $21.4M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Rock Springs Capital Management held 25,500 shares of Viking Therapeutics worth $995K as of Q2 2026.
  • Rock Springs Capital Management sold 70,500 Viking Therapeutics shares in Q2 2026, an estimated $2.28M.
  • Viking Therapeutics made up 0.05% of Rock Springs Capital Management's portfolio in Q2 2026, its #99 holding.
  • Rock Springs Capital Management first reported a position in Viking Therapeutics in Q3 2018 and has held it in 4 quarters since.
  • Rock Springs Capital Management's Viking Therapeutics position peaked at $21.4M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.